All Stories

  1. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

    Article • Current Medical Research and Opinion, August 2019, Taylor & Francis

    Pierre LEVY

  2. Migraine burden and costs in France: a nationwide claims database analysis of triptan users

    Article • Journal of Medical Economics, March 2019, Taylor & Francis

    Pierre LEVY

  3. Cost-effectiveness analyses using real-world data: an overview of the literature

    Article • Journal of Medical Economics, February 2019, Taylor & Francis

    Pierre LEVY, Ed Kennedy

  4. Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

    Article • Journal of Market Access & Health Policy, January 2019, Taylor & Francis

    Pierre LEVY

  5. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

    Article • Journal of Market Access & Health Policy, January 2019, Taylor & Francis

    Pierre LEVY

  6. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, September 2018, Taylor & Francis

    Pierre LEVY